Related Experiment Video
Updated: May 1, 2026

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
Published on: February 27, 2016
AROS has a context-dependent effect on SIRT1
Tarja Kokkola1, Tiina Suuronen1, Ferdinand Molnár1
1School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
Abstract:
The modulation of protein deacetylase SIRT1 has a vast therapeutic potential in treatment of several aging-associated diseases. Active regulator of SIRT1 (AROS) is a small endogenous protein which was originally reported to activate SIRT1 through a direct interaction in cancer cells. We show that the interaction between the two proteins is weak and does not alter the activity of SIRT1 in non-cancerous human cells. The results of different in vitro SIRT1 activity assays disclosed AROS as an inhibitor of SIRT1. The functional relationship between AROS and SIRT1 proved to be dependent on the biological context and experimental setting.
Insights
Active regulator of SIRT1 (AROS) does not activate SIRT1 in non-cancerous cells. Instead, AROS inhibits SIRT1 activity in vitro, revealing context-dependent interactions crucial for aging-associated disease research.
Area of Science:
- Biochemistry
- Molecular Biology
- Aging Research
Background:
- Sirtuin 1 (SIRT1) is a key protein deacetylase implicated in aging and age-related diseases.
- Active regulator of SIRT1 (AROS) was previously suggested to activate SIRT1, particularly in cancer cells.
Purpose of the Study:
- To investigate the interaction between AROS and SIRT1 in non-cancerous human cells.
- To determine the effect of AROS on SIRT1 activity in different experimental contexts.
Main Methods:
- Co-immunoprecipitation assays to assess protein-protein interactions.
- In vitro SIRT1 activity assays to measure enzyme function.
- Experiments conducted in non-cancerous human cell lines.
Main Results:
- The interaction between AROS and SIRT1 in non-cancerous cells was found to be weak.
- AROS did not alter SIRT1 activity in non-cancerous human cells.
- In vitro assays demonstrated that AROS acts as an inhibitor of SIRT1.
Conclusions:
- The functional relationship between AROS and SIRT1 is not a simple activation.
- AROS's effect on SIRT1 is context-dependent, varying with cell type and experimental conditions.
- These findings necessitate a re-evaluation of AROS as a therapeutic modulator for aging-associated diseases.
Related Concept Videos
Riboswitches
The aptamer has high specificity for a particular metabolite which allows riboswitches to specifically regulate...
Experimental RNAi
RNA Editing
Translational Regulation
tRNA Activation
tRNA Activation
